Figure S2. Survival Outcomes By Tumor PD-L1 Levels (arm B parts 1 and 2) from Open-label, Phase I Study of Nivolumab Combined with &lt;i&gt;nab&lt;/i&gt;-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer